True Prevalence of Hypercortisolism

EP: 1.Overview of the CATALYST Study for Hypercortisolism

EP: 2.Defining Difficult to Control Diabetes

EP: 3.CATALYST Trial Study Design

Now Viewing

EP: 4.True Prevalence of Hypercortisolism

EP: 5.Coexisting Cardiometabolic Conditions and Hypercortisolism

EP: 6.Engaging Primary Care Clinicians in Screening for Hypercortisolism

EP: 7.Spectrum of Hypercortisolism Presentations

EP: 8.Mifeprestone for Treatment of Hypercortisolism

EP: 9.Reconsidering Standard of Care for Hypercortisolism

Video content above is prompted by the following:

1. What were the key findings from Part 1: Prevalence phase of the CATALYST study?
2. How does the data from the CATALYST trial change the narrative about the true prevalence of hypercortisolism in diabetes?
3. How does this prevalence data fit with the growing body of evidence regarding autonomous adrenal cortisol secretion?
4. How would you respond to clinicians that reference “false positives” or “pseudo cushings” as an explanation to these findings?